Previous studies suggest that metabotropic glutamate 2/3 receptors are involved in psychiatric disorders. In this study, we examined the effects of the selective metabotropic glutamate 2/3 (mGlu2/3) receptor agonist MGS0028 on behavioral abnormalities in mice lacking the pituitary adenylate cyclase-activating polypeptide (PACAP), an experimental model of psychiatric disorders such as schizophrenia and attention-deficit/hyperactivity disorder. We found that PACAP-deficient mice showed impairments in the novel object recognition test and these impairments were improved by MGS0028 (0.1 mg/kg). Similarly, MGS0028 improved hyperactivity and jumping behaviors, but did not reverse increased immobility times in the forced swim test in PACAP-deficient mice. These results suggest that MGS0028 may be a potential, novel treatment for psychiatric disorders.
Introduction
The pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neuropeptide that acts as a neurotransmitter and as a neuromodulator (Vaudry et al., 2009) . Hashimoto et al. (2007 Hashimoto et al. ( , 2010 showed that PACAP gene single nucleotide polymorphisms are associated with schizophrenia and major depressive disorders, suggesting that PACAP may be a risk factor for psychiatric disorders. They also reported that PACAP-deficient (Adcyap1 -/ -) mice show behavioral abnormalities, such as hyperlocomotion and jumping behavior in the novel open-field test and prepulse inhibition deficits in a startle test, and these changes were improved by the atypical antipsychotic drug risperidone and the attention-deficit/hyperactivity disorder drugs amphetamine and methylphenidate (Hashimoto et al., 2001; Tanaka et al., 2006) . Therefore, Adcyap1
-/ -mice are considered an animal model that provides valid assessments of potential antipsychotic drugs.
A metabotropic glutamate (mGlu) 2/3 receptor agonist and an mGlu2 allosteric potentiator each inhibit amphetamine-induced and phencyclidine-induced hyperactivity (Galici et al., 2005; Johnson et al., 2005) . Moreover, mGlu2/3 receptor agonists ameliorate isolation rearinginduced hyperactivity and deficits of sensorimotor gating and recognition memory (Jones et al., 2011; Ago et al., 2012) . These findings suggest that activation of mGlu2/3 receptors may have therapeutic benefits for patients with psychiatric disorders such as schizophrenia. In this respect, we have previously found that Adcyap1 -/ -mice show both behavioral abnormalities and cognitive impairments. In the present study, we examined the effects of the potent and selective mGlu2/3 receptor agonist MGS0028, which has a very high affinity for mGlu2 (EC 50 = 0.57 nmol/l) and mGlu3 (EC 50 = 2.07 nmol/l) receptors (Nakazato et al., 2000; Ritzén et al., 2005) , on cognitive impairments, hyperactivity, jumping behavior, and depression-like behavior in Adcyap1 -/ -mice.
Methods

Subjects and drugs
All experiments were conducted in accordance with protocols approved by the Animal Care and Use Committee of the Graduate School of Pharmaceutical Sciences, Osaka University. Homozygous PACAP-null mutant mice were generated and characterized as described previously (Hashimoto et al., 2001) , and they were backcrossed for more than 10 generations onto CD1 mice. All mice used were obtained from the intercross of the heterozygous animals, and all experiments were conducted on 8-week-old to 10-week-old male mice. The wild-type control and Adcyap1 -/ -mice were housed separately under a standard 12 h light/dark cycle (lights on at 8:00 a.m.), at a constant temperature of 22±11C, with free access to food and water. MGS0028 (Taisho Pharmaceutical Co., Saitama, Japan) was dissolved in saline (0.9% NaCl) and adjusted to pH 7.4 with 0.5 mol/l NaOH. The drug was injected at 10 ml/kg intraperitoneally.
Open-field test
Each mouse was placed in the center of an open cubic transparent acrylic box with a black Plexiglas floor (45 cm Â 45 cm Â 30 cm) and allowed to explore the environment for 60 min. Their horizontal locomotor activities and jumping behaviors were monitored using an infrared photocell beam detection system (Acti-Track; Panlab, Barcelona, Spain) (Ishihama et al., 2010) .
Novel object recognition test
Each mouse was habituated by housing it in the test cage (22 cm Â 38 cm Â 20 cm) for 3 days. In each training session, two identical objects (yellow Lego blocks) were placed in the cage, and the mouse was allowed to explore the cage for 15 min. The retention sessions were conducted 6 h after the training sessions. In each 5-min retention session, the mouse was placed back in the test cages with a familiar object that had been presented in the training session and a novel object (wooden ball). The behaviors of the mice were videotaped and evaluated by observers blinded to the genotype and treatment conditions. The objects were fixed to the floor and cleaned thoroughly between trials to ensure the absence of olfactory cues. Exploratory preferences were calculated as the ratio of the time spent exploring the novel object versus the total time spent exploring both the familiar and the novel objects, and these ratios were used as the dependent measure of recognition memory.
Forced swim test
The forced swim test was carried out as reported previously (Ishihama et al., 2010) . The total immobility time was measured during the final 4 min of a 6-min swimming session by observers blinded to the genotype and treatment conditions.
Statistical analysis
All data were analyzed using two-way analysis of variance, followed by the Tukey-Kramer test. Statistical analyses were carried out using the software package Statview 5.0 J for Apple Macintosh (SAS Institute, Cary, North Carolina, USA). A value of P less than 0.05 was considered statistically significant. Effects of MGS0028 on recognition memory in Adcyap1 -/ -and wild-type mice in the novel object recognition test. After habituation, the wild-type or Adcyap1
-/ -mice were exposed to two identical objects in 15-min training sessions (a), and then the recognition memory was tested 6 h later with one of the familiar objects replaced by a novel object in 5-min retention sessions (b); MGS0028 (0.1 mg/kg) or vehicle was administered 1 h before the training session. The total exploratory time of the mouse in either the training or the retention session was measured, and the percentage of the total exploration time spent exploring the novel object was calculated. Values are expressed as the mean ± SEM of 8-9 mice/group. *P < 0.05, compared with vehicle-treated wild-type mice; wwP < 0.01, compared with vehicle-treated Adcyap1 -/ -mice. PACAP, pituitary adenylate cyclase-activating polypeptide.
Effect of mGluR2/3 agonist in PACAP-deficient mice Ago et al. 75 Results Figure 1 shows the effects of MGS0028 on novel object recognition in Adcyap1 -/ -and wild-type mice. The total exploratory time in either the training or the retention session did not differ between Adcyap1 -/ -and wild-type mice, and MGS0028 (0.1 mg/kg) did not affect exploratory behavior in either genotype (Fig. 1a and b, left) . In the retention session, the wild-type mice spent more time exploring the novel object than the familiar object, and this preference can be used as an index of object recognition. The Adcyap1 -/ -mice explored the novel object to the same extent as the familiar target, and the preference index in Adcyap1 -/ -mice was significantly lower than that in wild-type mice (Fig. 1b, right) . MGS0028 improved the impairment in recognition memory in Adcyap1 -/ -mice, whereas it did not affect cognitive performance in wild-type mice (the significant interaction between the genotype and treatment: F 1,31 = 5.10, P < 0.05). Figure 2 shows the effects of MGS0028 on hyperactivity, jumping behavior, and immobility in Adcyap1 -/ -mice. MGS0028 (0.1 and 0.3 mg/kg) did not affect locomotor activity in wild-type mice. Adcyap1 -/ -mice showed greater locomotor activity in a novel environment than wild-type mice, and this effect was inhibited by MGS0028 (F 2,58 = 3.24, P < 0.05) (Fig. 2a) . MGS0028 (0.1 and 0.3 mg/kg) also inhibited the jumping behavior of Adcyap1 -/ -mice (F 2,58 = 10.67, P < 0.001) (Fig. 2b) . Adcyap1 -/ -mice showed longer immobility times in the forced swim test than wild-type mice, but MGS0028 did not affect immobility times in either genotype (Fig. 2c) .
Discussion
The present study examined the effects of the mGlu2/3 receptor agonist MGS0028 on abnormal behaviors in Adcyap1 -/ -mice. We first found that Adcyap1 -/ -mice showed impaired recognition memory in the novel object recognition test. Consistent with this finding, Tajiri et al. (2012) reported that Adcyap1 -/ -mice showed impaired spatial working memory in the Y-maze test. Taken together with previous behavioral studies in Adcyap1 -/ -mice (Hashimoto et al., 2001 (Hashimoto et al., , 2009 Tanaka et al., 2006) , this supported the use of Adcyap1 -/ -mice to assess potential antipsychotic drugs. The present study showed that MGS0028 improved the impaired recognition memory, hyperactivity, and jumping behavior, but not immobility in the forced swim test, in Adcyap1 -/ -mice.
In the novel object recognition test, the total time spent exploring the objects was not altered in Adcyap1 -/ -mice, which are hyperactive in a novel environment. This may be because we performed 3 days of habituation to the test cage. Under these conditions, MGS0028 improved the deficits of recognition memory in Adcyap1 -/ -mice. Similarly, Jones et al. (2011) found that LY379268, an mGlu2/3 receptor agonist, improved recognition memory deficits in isolation-reared rats. However, Horiguchi et al. (2011) reported that LY379268 did not affect impaired recognition in subchronic phencyclidine-treated rats. Moreover, MGS0028 improved hyperactivity and jumping behavior, but not immobility, in Adcyap1 -/ -mice. This reversal of hyperactivity is consistent with previous reports that mGlu2/3 receptor agonists inhibit amphetamine-induced and phencyclidine-induced hyperactivity [for a review, see Chaki (2010) ], and it is similar to the effects of the atypical antipsychotic drug risperidone (Hashimoto et al., 2007) . In addition, the lack of effects on immobility in the forced swim test is similar to the lack of effects of the typical antipsychotic drug haloperidol (Hashimoto et al., 2009 ). As such, each abnormal behavior of Adcyap1 -/ -mice shows different sensitivity to antipsychotic drugs, and it is likely that these abnormal behaviors are mediated by different mechanisms.
In clinical studies of the mGlu2/3 receptor agonist, Patil et al. (2007) reported that LY2140023, the methionine amide prodrug of the selective mGlu2/3 receptor agonist LY404039, elicited a significant greater improvement in both positive and negative symptoms in schizophrenia, whereas Kinon et al. (2011) reported an inconclusive result. After the submission of this paper, Eli Lilly and Company unfortunately has reported negative results from the H8Y-MC-HBBM study investigating LY2140023 for the treatment of patients with an acute exacerbation of schizophrenia (http://newsroom.lilly.com/releasedetail.cfm? releaseid = 690836). Therefore, it is not known whether the mGlu2/3 receptor is actually a priority target for the treatment of schizophrenia.
Conclusion
The present study showed that recognition memory is impaired in Adcyap1 -/ -mice, and MGS0028 improved the impaired recognition, hyperactivity, and jumping behavior in Adcyap1 -/ -mice. Pozzi et al. (2011) have recently reported that the mGlu2/3 receptor agonist LY379268 reduced (R)-CPP-induced impairment in attentional functioning and impulsivity. Taken together, it is likely that the mGlu2/3 receptor might be a potential target for the treatment of psychiatric disorders such as attention-deficit/hyperactivity disorder.
